ACG 2021 Annual Scientific Meeting

Join GI physicians from the U.S. and around the world for the ACG Annual Scientific Meeting. ACG 2021 will deliver the latest clinical information on timely topics in gastroenterology and hepatology.

Register for any two courses and save up to 10%!

Can’t join us in-person in Las Vegas?
Maximize your learning with one of our VIRTUAL All-Access Pass options and save 20%!

ACG All-Access Pass: The ACG All-Access Pass includes virtual-only access to the GI Pathophysiology Course, GI Pharmacology Course, Practice Management Summit, Postgraduate Course + Bonus Sessions (formerly Learning Luncheons), and the Annual Scientific Meeting + Bonus Sessions (formerly Breakfast Sessions). Registrants will also receive online access to the 2021 Self-Assessment Test.

NEW for 2021: ACG All-Access Pass + ASGE Endoscopy Course: The ACG All-Access Pass includes virtual-only access to all of the courses in the ACG All-Access Pass PLUS the ASGE Endoscopy Course.

Wednesday, October 27, 2021 | 8:30 am - 12:15 pm
8:30 am Simultaneous Plenary Sessions 4
10:15 am Break
10:20 am David Y. Graham Lecture

Navigating the Road From Precision to Prevention in IBD
Presenter: Marla C. Dubinsky, MD
Introduced by: David A. Greenwald, MD, FACG

Discuss biomarkers for monitoring inflammation, using prognostic factors to guide IBD therapy, and explain the preclinical phase of IBD.

10:50 am Break
11:00 am Simultaneous Symposia: Session 5
In-person attendees can choose from two simultaneous symposia. One of the two symposia will be livestreamed for virtual attendees to view. All attendees will have access to on-demand recordings from both symposia following the conference.


Symposium 5A: Fecal Microbiota Transplantation at a Crossroads: Where Are We Now and Where Are We Going?
Moderator: Paul Feuerstadt, MD, FACG

  • A Clinician’s Crash Course to Understanding the Microbiota
    Paul Feuerstadt, MD, FACG
    Review what the microbiota is and how it is measured and evaluated, recognize what a “normal” microbiota consortium looks like, and define the most common terms used in this field.
  • The Future of Microbiota Restoration in C. difficile Infections
    Sahil Khanna, MD, FACG
    Identify the newest investigational microbiota replacement therapy products used to treat C. difficile infection.
  • Microbiota Restoration in Inflammatory Bowel Disease, Irritable Bowel Syndrome, and Liver Disease
    Olga C. Aroniadis, MD, MSc
    Describe the alterations in the microbiota seen in non-C. difficile infection gastrointestinal diseases, and explain what the next 1-2 years of research might look like with regard to applying microbiota therapy to these disease states.

Symposium 5B: Recent Developments in Esophageal Motility Disorders
Moderator: Katarina B. Greer, MD, MS Epi

  • Achalasia Guideline: Breaking It Down – Diagnosis, Pearls, Subtype, Management
    Katarina B. Greer, MD, MS Epi
    Discuss the common subtypes of achalasia, diagnosis and best management strategies, and how to manage treatment failures.
  • The New Chicago Classification Version 4.0: Implications for Clinical Practice
    John E. Pandolfino, MD, MSCI, FACG
    Review the new Chicago classification of esophageal motility disorders and discuss its implications for clinical practice.
  • EGJOO and Opioid-Induced Esophageal Dysfunction: Extra Considerations in Diagnosis, Treatment, and Management
    Marcelo F. Vela, MD, MSCR, FACG
    Describe esophagogastric junction outflow obstruction diagnosis, differential diagnosis, and management options.
12:15 pm Annual Scientific Meeting Adjourns